Company research
GERON CORP
CIK 886744Updated Nov 17, 2026
Historical securities (1)
GERNW · OTC · warrant · closed Dec 31, 2025GERN price & chart
Loading TradingView…
NASDAQ:GERN on TradingView ↗About the company
meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
In the news
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm May 12, 2025, 09:54 ET Share this article Share to X Share this article Share to X LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law ↗
GERN Deadline: GERN Investors with Losses in Excess of $100K Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. May 09, 2025, 14:45 ET Share this article Share to X Share this article Share to X NEW YORK , May 9, 2025 /PRNewswire/ -- Why: R ↗
Recent filings
4 filing
4 filing
SCHEDULE 13G - filed by STATE STREET CORP regarding GERON CORP
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 567,382,000Source | 444,950,000Source | 519,009,000Source | 555,198,000Source | 449,399,000Source | 534,120,000Source | 562,450,000Source | 482,074,000Source | 570,540,000Source | 593,781,000Source | 394,076,000Source | 190,575,000Source |
| Property, Plant and Equipment, NetUSD | 973,000Source | 1,595,000Source | 1,089,000Source | 1,189,000Source | 1,626,000Source | 1,000,000Source | 1,147,000Source | 1,681,000Source | 884,000Source | 1,310,000Source | 1,177,000Source | 793,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 78,117,000Source | 60,344,000Source | 62,643,000Source | 77,734,000Source | 116,945,000Source | 68,895,000Source | 83,745,000Source | 189,761,000Source | 77,560,000Source | 79,016,000Source | 70,023,000Source | 56,845,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 35,361,000Source | 28,007,000Source | 51,640,000Source | 36,608,000Source | 874,000Source | 41,882,000Source | 31,166,000Source | — | 36,987,000Source | 35,946,000Source | — | — |
| Inventory, NetUSD | 95,422,000Source | 20,283,000Source | 123,604,000Source | 69,125,000Source | 774,000Source | 133,287,000Source | 56,222,000Source | — | 116,636,000Source | 38,714,000Source | — | — |
| Assets, CurrentUSD | 522,342,000Source | 398,057,000Source | 486,339,000Source | 505,595,000Source | 373,308,000Source | 498,531,000Source | 495,769,000Source | 451,509,000Source | 520,271,000Source | 490,992,000Source | 341,348,000Source | 180,246,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,856,000Source | 6,057,000Source | 6,495,000Source | 7,256,000Source | 5,551,000Source | 6,864,000Source | 6,822,000Source | 5,712,000Source | 4,610,000Source | 5,053,000Source | 4,879,000Source | 3,992,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,339,000Source | 3,055,000Source | 1,763,000Source | 2,523,000Source | 3,225,000Source | 1,959,000Source | 2,704,000Source | 3,392,000Source | 2,151,000Source | 2,881,000Source | 3,556,000Source | 4,147,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | — | 300,395,000Source | — | — | 305,012,000Source | — | — | 344,668,000Source | 313,461,000Source | 146,127,000Source | 110,577,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | 0Source | — | — | 0Source | — | — | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 638,000Source | 603,000Source | 642,000Source | 638,000Source | 601,000Source | 641,000Source | 637,000Source | 591,000Source | 640,000Source | 606,000Source | 545,000Source | 390,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,826,979,000Source | -1,746,989,000Source | -1,876,163,000Source | -1,808,551,000Source | -1,720,542,000Source | -1,859,483,000Source | -1,792,176,000Source | -1,653,159,000Source | -1,855,841,000Source | -1,772,341,000Source | -1,597,769,000Source | -1,413,642,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 408,000Source | 1,017,000Source | -339,000Source | 117,000Source | -537,000Source | -191,000Source | 304,000Source | -273,000Source | 269,000Source | 261,000Source | 185,000Source | -219,000Source |
| Stockholders' Equity Attributable to ParentUSD | 248,707,000Source | 292,284,000Source | 218,614,000Source | 259,531,000Source | 306,695,000Source | 229,108,000Source | 268,238,000Source | 344,868,000Source | 225,872,000Source | 280,320,000Source | 247,949,000Source | 79,998,000Source |
| Additional Paid in Capital, Common StockUSD | 2,074,640,000Source | 2,037,653,000Source | 2,094,474,000Source | 2,067,327,000Source | 2,027,173,000Source | 2,088,141,000Source | 2,059,473,000Source | 1,997,709,000Source | 2,080,804,000Source | 2,051,794,000Source | 1,844,988,000Source | 1,493,469,000Source |
| Liabilities and EquityUSD | 567,382,000Source | 444,950,000Source | 519,009,000Source | 555,198,000Source | 449,399,000Source | 534,120,000Source | 562,450,000Source | 482,074,000Source | 570,540,000Source | 593,781,000Source | 394,076,000Source | 190,575,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 87,712,000Source | 137,933,000Source | 70,331,000Source | 64,283,000Source | 103,540,000Source | 73,570,000Source | 63,034,000Source | 123,158,000Source | 111,542,000Source | 88,298,000Source | 108,070,000Source | 76,694,000Source |
| Operating Lease, Liability, CurrentUSD | 994,000Source | 968,000Source | 1,013,000Source | 987,000Source | 961,000Source | 1,007,000Source | 981,000Source | 955,000Source | 1,000,000Source | 974,000Source | 949,000Source | 925,000Source |
| Accounts Payable, CurrentUSD | 11,111,000Source | 13,734,000Source | 8,805,000Source | 8,226,000Source | 5,620,000Source | 12,720,000Source | 8,032,000Source | 9,992,000Source | 11,257,000Source | 8,595,000Source | 6,161,000Source | 10,190,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,658,000Source | 2,458,000Source | 1,000,000Source | 1,865,000Source | 2,645,000Source | 1,226,000Source | 2,069,000Source | 2,829,000Source | 1,445,000Source | 2,266,000Source | 3,006,000Source | 3,671,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 39,928,000Source | 36,489,000Source | 30,715,000Source | 26,294,000Source | 38,660,000Source | 30,965,000Source | 28,886,000Source | 33,891,000Source | 51,340,000Source | 35,549,000Source | 40,308,000Source | 33,100,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 682,000Source | 1,000,000Source | 1,100,000Source |
| Long-term Debt, Current MaturitiesUSD | — | 71,562,000Source | — | — | 46,917,000Source | — | — | 71,526,000Source | — | — | 46,893,000Source | 20,945,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 119,264,000Source | 12,275,000Source | 120,131,000Source | 118,991,000Source | 36,519,000Source | 119,833,000Source | 118,728,000Source | 11,219,000Source | 119,547,000Source | 118,476,000Source | 35,051,000Source | 30,212,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,913,000Source | 7,423,000Source | 26,659,000Source | 31,185,000Source | 18,526,000Source | 8,001,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 4,894,000Source | -4,649,000Source | 991,000Source | 35,695,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 16,651,000Source | 17,508,000Source | 77,922,000Source | 37,971,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,463,000Source | -563,000Source | 2,661,000Source | 2,435,000Source | -4,029,000Source | 3,503,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -62,906,000Source | -47,979,000Source | -111,037,000Source | -218,618,000Source | -167,743,000Source | -127,379,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 51,856,000Source | 52,439,000Source | 107,247,000Source | -106,004,000Source | -180,322,000Source | 62,067,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | 680,000Source | 830,000Source | 431,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,425,000Source | 256,000Source | 2,267,000Source | 334,372,000Source | 362,021,000Source | 87,264,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 86,554,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -8,661,000Source | 4,734,000Source | -1,436,000Source | 9,738,000Source | 13,929,000Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 11,712,000Source | 10,364,000Source | -7,017,000Source | 5,154,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -36,000Source | 18,000Source | 87,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,742,000Source | 6,890,000Source | — | 6,738,000Source | — | 7,408,000Source | 25,443,000Source | 31,927,000Source | 18,525,000Source | 8,001,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 286,000Source | 253,000Source | 1,071,000Source | -3,108,000Source | 1,088,000Source | 1,327,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | -1,707,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 69,135,000Source | 43,628,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 75,000Source | 449,000Source | — | — |
| InterestExpenseNonoperatingUSD | — | — | 8,644,000Source | 3,046,000Source | 7,146,000Source | 8,516,000Source | 7,147,000Source | 8,200,000Source | 32,657,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 4,264,000Source | 4,877,000Source | 2,971,000Source | 4,656,000Source | 3,421,000Source | 5,152,000Source | 18,117,000Source | 19,607,000Source | 18,152,000Source | 2,529,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,428,000Source | -26,447,000Source | -16,680,000Source | -16,375,000Source | -3,642,000Source | -19,835,000Source | -83,500,000Source | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Operating Costs and ExpensesUSD | — | — | 1,043,000Source | 456,000Source | 9,240,000Source | 1,190,000Source | 1,692,000Source | 1,206,000Source | 4,745,000Source | 1,256,000Source | — | — |
| Operating ExpensesUSD | — | — | 61,114,000Source | 56,486,000Source | 69,976,000Source | 61,490,000Source | 51,679,000Source | 56,307,000Source | 252,466,000Source | 250,726,000Source | 194,181,000Source | 139,146,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -161,000Source | -63,000Source | -9,000Source | -61,000Source | -74,000Source | -83,000Source | -375,000Source | -236,000Source | -23,000Source | 1,002,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 121,120,000Source | 29,700,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | 98,884,000Source | — | 371,608,000Source | 296,102,000Source | 320,505,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 1,500,000Source | 31.6Source | 12,356,000Source | 1,799,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | 26,747,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 47,227,000Source | 28,271,000Source | 57,480,000Source | 49,036,000Source | 51,837,000Source | 39,603,000Source | — | — | 237,000Source | 596,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 39,001,000Source | 35,877,000Source | 38,863,000Source | 38,564,000Source | 35,425,000Source | 40,023,000Source | 159,256,000Source | 145,732,000Source | — | — |
| Operating Income (Loss)USD | — | — | -13,887,000Source | -28,215,000Source | -12,496,000Source | -12,454,000Source | 158,000Source | -16,704,000Source | -68,585,000Source | -173,732,000Source | -193,944,000Source | -138,550,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -161,000Source | -63,000Source | -9,000Source | -61,000Source | -74,000Source | -83,000Source | -375,000Source | -236,000Source | -23,000Source | 1,002,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -83,425,000Source | -174,521,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 75,000Source | 449,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,428,000Source | -26,447,000Source | -16,680,000Source | -16,375,000Source | -3,642,000Source | -19,835,000Source | -83,500,000Source | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.03Source | -0.04Source | -0.02Source | -0.02Source | -0.01Source | -0.03Source | -0.13Source | -0.27Source | -0.32Source | -0.37Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.03Source | -0.04Source | -0.02Source | -0.02Source | -0.01Source | -0.03Source | -0.13Source | -0.27Source | -0.32Source | -0.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 667,101,756Source | 662,158,182Source | 670,696Source | 666,170Source | 669,375Source | 665,905Source | 666,662,989Source | 646,033,247Source | 570,645,405Source | 380,784,846Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 667,101,756Source | 662,158,182Source | 670,696Source | 666,170Source | 669,375Source | 665,905Source | 666,662,989Source | 646,033,247Source | 570,645,405Source | 380,784,846Source |
| Interest Expense (non-operating)USD | — | — | 8,644,000Source | 3,046,000Source | 7,146,000Source | 8,516,000Source | 7,147,000Source | 8,200,000Source | 32,657,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 134,000Source | 131,000Source | 474,000Source | 546,000Source | 442,000Source | 288,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 69,135,000Source | 43,628,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -82,358,000Source | -174,737,000Source | — | — |
| Interest ExpenseUSD | — | — | — | 3,046,000Source | — | — | — | — | — | 18,504,000Source | 8,312,000Source | 6,882,000Source |
| Investment Income, InterestUSD | — | — | 4,264,000Source | 4,877,000Source | 2,971,000Source | 4,656,000Source | 3,421,000Source | 5,152,000Source | 18,117,000Source | 19,607,000Source | 18,152,000Source | 2,529,000Source |
| Operating Costs and ExpensesUSD | — | — | 1,043,000Source | 456,000Source | 9,240,000Source | 1,190,000Source | 1,692,000Source | 1,206,000Source | 4,745,000Source | 1,256,000Source | — | — |
| Operating ExpensesUSD | — | — | 61,114,000Source | 56,486,000Source | 69,976,000Source | 61,490,000Source | 51,679,000Source | 56,307,000Source | 252,466,000Source | 250,726,000Source | 194,181,000Source | 139,146,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | 26,747,000Source | — | — | — |
Offerings
Registration 333-293907
Filing attachments
d188608dex991.htm · 8-K · 2026-11-04
Exhibit 99.1 Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range; lowered 2026 total operating expenses range to $220 million to $230 million Initiated gated commercial launch to expand RYTELO access to eligible LR-MDS patients …
Read attachment ↗d43013dex991.htm · 8-K · 2026-10-28
Exhibit 99.1 Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis FOSTER CITY, Calif., - October 28, 2026 - Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decision was based on a recommendation from the independent Data Monitoring Commi…
Read attachment ↗d158179dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d158179dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash…
Read attachment ↗d118024dex45.htm · S-3ASR · 2026-03-02
EXHIBIT 4.5 GERON CORPORATION Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE O…
Read attachment ↗d118024dex46.htm · S-3ASR · 2026-03-02
EXHIBIT 4.6 GERON CORPORATION AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________ 1 GERON CORPORATION FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “ Agreement ”), dated as of [•], between GERON CORPORATION, a Delaware corporation (the “ Company ”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant age…
Read attachment ↗d118024dex47.htm · S-3ASR · 2026-03-02
EXHIBIT 4.7 GERON CORPORATION AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________ GERON CORPORATION FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between GERON CORPORATION, a Delaware corporation (the “Company ”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant …
Read attachment ↗